Eagle Pharmaceuticals has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to conduct a study to evaluate the neuroprotective effects of Ryanodex (dantrolene sodium).
The study will be conducted under a Cooperative Research and Development Agreement (CRADA), a written agreement that allows government laboratories to partner with private industries or academia on research and development projects. Eagle will bear all costs associated with the study.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
While the standard treatment of atropine and oxime is essential after exposure to a nerve agent, these drugs are not neuroprotective. If approved, Ryanodex would represent a first of its kind agent as a neuroprotective treatment for the amelioration of neurological damage due to nerve agent exposure. Nerve agent exposure often results in death.
“We are delighted to be working with the U.S. Military on this important study to evaluate Ryanodex as a neuroprotective therapy in nerve agent exposure, a potential new indication for the drug,” said Scott Tarriff, Chief Executive Officer of Eagle.